Accumulating reports have demonstrated that GSK3β is highly expressed in GBM compared to non-malignant brain tissues, and plays a significant role as a promoter of neoplastic GBM phenotypes, making it a potential biomarker for targeted therapy [19,43,44]. The gene discussed is GSK3B; the disease is glioblastoma.